High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

摘要

High-dose melphalan (HDM) is the recommended conditioning regimen for autologous hematopoietic stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). Various strategies have been employed to optimize HDM conditioning for ASCT; however, these strategies have proved ineffective because of associated toxicities [1,2].